首页 > 最新文献

Advances in Hematology and Oncology Research最新文献

英文 中文
Distribution of Cancer of Multiple Myeloma in Jamaica 2008 2008 年牙买加多发性骨髓瘤癌症分布情况
Pub Date : 2023-07-18 DOI: 10.33140/ahor.06.02.01
Laten Andre, Mclish
Objective: To determine the distribution of multiple myeloma in Jamaica 2008. Methods: The study included all fourteen parishes. Data obtained from the Jamaica Cancer Registry located in the Pathology Department of the University of the West Indies. Population denominators obtained from the 2011 census taken by the Statistical Institute of Jamaica. The statistical package which was used to analyze the data was excel. Results: Onset of multiple myeloma (MM) in Jamaica 2008 began in the age group 20 years to 24 years. The highest frequencies occurred in the age groups 60 years to 64 years, 70 years to 74 years and 75 years to 79 years. The median age at which MM was diagnosed was 69 years. These results indicate that age is an important risk factor in developing multiple myeloma. The crude incidence rate (CIR) was determined for both sexes in Jamaica 2008. In the case of males, the CIR for multiple myeloma was 1.5 and in the case of females, the CIR for multiple myeloma was 1.0, (male/female ratio, 1.5). Hence, there was a greater probability of males developing multiple myeloma compared to females. The CIR used to determine the probability of someone developing multiple myeloma in each parish in Jamaica. Kingston and St. Andrew were treated as one as they are so interwoven. The highest probability of developing multiple myeloma was for someone residing in Manchester (2.6), Kingston and St. Andrew (2.3), St. Ann (1.7), St. Catherine (1.5), Portland (1.2) and St. Thomas (1.1). Conclusion: In mitigating multiple myeloma, it is important that the public be educated regarding the risk factors associated with this cancer such as age, sex, race and family history. It is also critical that screening is done by 45 years of age.
目的:确定多发性骨髓瘤在牙买加 2008 年的分布情况:确定 2008 年牙买加多发性骨髓瘤的分布情况。研究方法:研究对象包括所有十四个教区。数据来自西印度群岛大学病理学系的牙买加癌症登记处。人口分母来自牙买加统计研究所进行的2011年人口普查。用于分析数据的统计软件包为 excel。结果2008年牙买加多发性骨髓瘤(MM)的发病年龄段为20至24岁。发病率最高的年龄组为 60 至 64 岁、70 至 74 岁和 75 至 79 岁。MM的诊断年龄中位数为69岁。这些结果表明,年龄是罹患多发性骨髓瘤的一个重要风险因素。牙买加确定了 2008 年男女粗发病率。男性多发性骨髓瘤的粗发病率为 1.5,女性多发性骨髓瘤的粗发病率为 1.0(男女比例为 1.5)。因此,男性患多发性骨髓瘤的概率高于女性。CIR 用于确定牙买加各教区的多发性骨髓瘤患病概率。金斯敦和圣安德鲁被视为一个教区,因为这两个教区相互交织。居住在曼彻斯特(2.6)、金斯敦和圣安德鲁(2.3)、圣安(1.7)、圣凯瑟琳(1.5)、波特兰(1.2)和圣托马斯(1.1)的人患多发性骨髓瘤的概率最高。结论为了减少多发性骨髓瘤的发病率,必须向公众宣传与这种癌症相关的风险因素,如年龄、性别、种族和家族史。此外,在 45 岁之前进行筛查也至关重要。
{"title":"Distribution of Cancer of Multiple Myeloma in Jamaica 2008","authors":"Laten Andre, Mclish","doi":"10.33140/ahor.06.02.01","DOIUrl":"https://doi.org/10.33140/ahor.06.02.01","url":null,"abstract":"Objective: To determine the distribution of multiple myeloma in Jamaica 2008. Methods: The study included all fourteen parishes. Data obtained from the Jamaica Cancer Registry located in the Pathology Department of the University of the West Indies. Population denominators obtained from the 2011 census taken by the Statistical Institute of Jamaica. The statistical package which was used to analyze the data was excel. Results: Onset of multiple myeloma (MM) in Jamaica 2008 began in the age group 20 years to 24 years. The highest frequencies occurred in the age groups 60 years to 64 years, 70 years to 74 years and 75 years to 79 years. The median age at which MM was diagnosed was 69 years. These results indicate that age is an important risk factor in developing multiple myeloma. The crude incidence rate (CIR) was determined for both sexes in Jamaica 2008. In the case of males, the CIR for multiple myeloma was 1.5 and in the case of females, the CIR for multiple myeloma was 1.0, (male/female ratio, 1.5). Hence, there was a greater probability of males developing multiple myeloma compared to females. The CIR used to determine the probability of someone developing multiple myeloma in each parish in Jamaica. Kingston and St. Andrew were treated as one as they are so interwoven. The highest probability of developing multiple myeloma was for someone residing in Manchester (2.6), Kingston and St. Andrew (2.3), St. Ann (1.7), St. Catherine (1.5), Portland (1.2) and St. Thomas (1.1). Conclusion: In mitigating multiple myeloma, it is important that the public be educated regarding the risk factors associated with this cancer such as age, sex, race and family history. It is also critical that screening is done by 45 years of age.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139358032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case Report of Primary Central Nervous T-Cell Lymphoma in an Immunologically Competent Patient 免疫正常患者原发性中枢神经t细胞淋巴瘤1例报告
Pub Date : 2023-05-12 DOI: 10.33140/ahor.06.01.04
Case Report, Ait El Filali
Primary central nervous system (CNS) lymphomas are relatively rare, with the most common subtype being diffuse large B-cell lymphoma. Primary CNS T-cell lymphomas (PCNSTL) represent less than 5% of CNS lymphomas [1-2].
原发性中枢神经系统(CNS)淋巴瘤相对罕见,最常见的亚型是弥漫性大b细胞淋巴瘤。原发性中枢神经系统t细胞淋巴瘤(PCNSTL)占中枢神经系统淋巴瘤的比例不到5%[1-2]。
{"title":"A Case Report of Primary Central Nervous T-Cell Lymphoma in an Immunologically Competent Patient","authors":"Case Report, Ait El Filali","doi":"10.33140/ahor.06.01.04","DOIUrl":"https://doi.org/10.33140/ahor.06.01.04","url":null,"abstract":"Primary central nervous system (CNS) lymphomas are relatively rare, with the most common subtype being diffuse large B-cell lymphoma. Primary CNS T-cell lymphomas (PCNSTL) represent less than 5% of CNS lymphomas [1-2].","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129878132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laboratory Practice of Reference Intervals Modification for Children’s Blood Cell Analysis in China 中国儿童血细胞分析参考区间修改的实验室实践
Pub Date : 2023-04-24 DOI: 10.33140/ahor.06.01.03
Researc H Article, Yanjun Diao, Xiaoyan Hao, Enliang Hu, Bingbing Zhu, Jiawei Gao, Xiang Cheng, Jing Jing, Yuan Zhao, Jingyuan Jia, Chong Yuan, Jie Lin, Jiayun Liu
Background: The unreliability of reference intervals (RIs) for children’s blood cell analysis has led to an unnecessary effort in interpreting results. The Standard published in 2021 is expected to solve this problem in China but should be clinically evaluated before its application. In this study, we aim to analyse the advantages and disadvantages of the new reference intervals (RIs) and realize the optimization based on clinical communication with pediatricians. Methods: Compared with the laboratory’s original reference intervals (RIs), the RIs’ numerical trends were mapped and analysed, and the data of the past seven years were retrospectively re-interpreted. Pediatricians were then consulted to discuss the data analyses. Results: Basically, the new reference intervals (RIs) characterized with more detailed age stratification and two specimen types. The numerical range of some parameters was wider while some were unilaterally shifted. Retrospective analysis showed that the revised reference intervals (RIs) could correct previously abnormal results to the normal range in a large proportion. The recovery ratio of three lineage cells was white blood cells > red blood cells > platelets, and the ratio sorted by age is 28 days~1-year-old > 1~13years old > 13~18 years old. The leukocyte recovery ratio of 28 days~1-year was the largest, approximately 55% to 83%. Pediatricians recognized the value of the new reference intervals (RIs). The only exception is that the platelets’ reference intervals (RIs) were too broad, recommending maintaining the original RI. The missing 0~28-day’s reference intervals (RIs) were recommended to be supplemented with other reference books. Conclusions: The new reference intervals (RIs) were optimized and, combined with clinical feedback, produced new reference intervals (RIs) derived from accumulated experience, evolving a better set of RIs.
背景:儿童血细胞分析参考区间(RIs)的不可靠性导致了解释结果的不必要努力。2021年发布的标准有望解决中国的这一问题,但在应用前应进行临床评估。在本研究中,我们旨在通过与儿科医生的临床交流,分析新参考区间(RIs)的优缺点,并实现优化。方法:与实验室原始参考区间(RIs)比较,绘制RIs数值变化趋势图并进行分析,并对近7年资料进行回顾性重新解释。然后咨询儿科医生讨论数据分析。结果:基本上,新的参考区间(RIs)具有更详细的年龄分层和两种标本类型。有些参数的数值范围较宽,而有些参数则是单方面移动的。回顾性分析表明,修正后的参考区间(RIs)可以很大程度上将以前的异常结果纠正到正常范围。3种系细胞的回收率依次为白细胞>红细胞>血小板,按年龄排序为28天~1岁> 1~13岁> 13~18岁。28天~1年的白细胞回收率最大,约为55% ~ 83%。儿科医生认识到新的参考区间(RIs)的价值。唯一的例外是血小板参考区间(RIs)太宽,建议维持原来的RI。缺失的0~28天参考资料间隔(RIs)建议补充其他参考书。结论:对新的参考区间(RIs)进行了优化,并结合临床反馈,在积累经验的基础上产生了新的参考区间(RIs),形成了一套更好的RIs。
{"title":"Laboratory Practice of Reference Intervals Modification for Children’s Blood Cell Analysis in China","authors":"Researc H Article, Yanjun Diao, Xiaoyan Hao, Enliang Hu, Bingbing Zhu, Jiawei Gao, Xiang Cheng, Jing Jing, Yuan Zhao, Jingyuan Jia, Chong Yuan, Jie Lin, Jiayun Liu","doi":"10.33140/ahor.06.01.03","DOIUrl":"https://doi.org/10.33140/ahor.06.01.03","url":null,"abstract":"Background: The unreliability of reference intervals (RIs) for children’s blood cell analysis has led to an unnecessary effort in interpreting results. The Standard published in 2021 is expected to solve this problem in China but should be clinically evaluated before its application. In this study, we aim to analyse the advantages and disadvantages of the new reference intervals (RIs) and realize the optimization based on clinical communication with pediatricians. Methods: Compared with the laboratory’s original reference intervals (RIs), the RIs’ numerical trends were mapped and analysed, and the data of the past seven years were retrospectively re-interpreted. Pediatricians were then consulted to discuss the data analyses. Results: Basically, the new reference intervals (RIs) characterized with more detailed age stratification and two specimen types. The numerical range of some parameters was wider while some were unilaterally shifted. Retrospective analysis showed that the revised reference intervals (RIs) could correct previously abnormal results to the normal range in a large proportion. The recovery ratio of three lineage cells was white blood cells > red blood cells > platelets, and the ratio sorted by age is 28 days~1-year-old > 1~13years old > 13~18 years old. The leukocyte recovery ratio of 28 days~1-year was the largest, approximately 55% to 83%. Pediatricians recognized the value of the new reference intervals (RIs). The only exception is that the platelets’ reference intervals (RIs) were too broad, recommending maintaining the original RI. The missing 0~28-day’s reference intervals (RIs) were recommended to be supplemented with other reference books. Conclusions: The new reference intervals (RIs) were optimized and, combined with clinical feedback, produced new reference intervals (RIs) derived from accumulated experience, evolving a better set of RIs.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133287304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What about Non-AIDS Associated Kaposi’s Sarcoma? Clinical Features and Efficacy of Chemotherapy: A Monocentric Experience 非艾滋病相关的卡波西肉瘤呢?化疗的临床特征和疗效:单中心经验
Pub Date : 2023-04-21 DOI: 10.33140/ahor.06.01.02
Researc H Article, Khadija Darif, N. Ghozali, Y. Sbaiti, M. Meliani, FZ M Amziren, EL Mrabet
Background: Kaposi’s sarcoma is a mesenchymal proliferative process of blood and lymphatic system cells. The must well-known risk factors are immunosuppression and human herpes virus. Non-HIV related Kaposi’s sarcoma is a rare indolent entity that is more common among people of Mediterranean origin. Patients and Methods: The purpose of this retrospective analysis was to review a series of 21 patients with nonAIDS associated Kaposi’s sarcoma who presented to the Department of Oncology at the University Hospital Tangier between 2017 and 2022. Data were extracted from medical records using a pre-established survey sheet. The objective of this work is to define the major clinical features, treatment outcomes, and risk factors of the classic Mediterranean form of the disease in North Africa. Results: Twenty-one patients with non-AIDS associated Kaposi’s sarcoma were identified, with ages ranging from 52 to 98 years; the male-to-female ratio was 17:3. All of our patients had the classic form of the disease with negative HIV serology. In 71% of cases, Kaposi’s sarcoma was limited to the skin, without lymph node or visceral involvement. The lesions were multiple in all cases, mostly bilateral, and most commonly localized to the skin of the lower extremities. A complete response was achieved in 50% of patients using systemic therapy, and no patients died from Kaposi’s sarcoma. Conclusion: Unlike Kaposi’s sarcoma in AIDS patients, non-AIDS associated Kaposi’s sarcoma from Mediterranean countries is less agressive and more responsive to systemic therapeutic strategies.
背景:卡波西肉瘤是一种血液和淋巴系统细胞间充质增生过程。众所周知的危险因素是免疫抑制和人类疱疹病毒。非hiv相关的卡波西肉瘤是一种罕见的惰性实体,在地中海裔人群中更为常见。患者和方法:本回顾性分析的目的是回顾2017年至2022年间在丹吉尔大学医院肿瘤科就诊的21例非艾滋病相关卡波西肉瘤患者。使用预先建立的调查表从医疗记录中提取数据。这项工作的目的是确定北非经典地中海形式疾病的主要临床特征、治疗结果和危险因素。结果:21例非艾滋病相关性卡波西肉瘤患者,年龄52 ~ 98岁;男女比例为17:3。我们所有的病人都有典型的艾滋病形式,HIV血清学阴性。在71%的病例中,卡波西氏肉瘤局限于皮肤,没有淋巴结或内脏受累。所有病例的病变都是多发的,大多数是双侧的,最常见的是局限于下肢皮肤。使用全身治疗的患者中有50%达到完全缓解,没有患者死于卡波西氏肉瘤。结论:与艾滋病患者的卡波西肉瘤不同,来自地中海国家的非艾滋病相关性卡波西肉瘤侵袭性较低,对全身治疗策略反应较好。
{"title":"What about Non-AIDS Associated Kaposi’s Sarcoma? Clinical Features and Efficacy of Chemotherapy: A Monocentric Experience","authors":"Researc H Article, Khadija Darif, N. Ghozali, Y. Sbaiti, M. Meliani, FZ M Amziren, EL Mrabet","doi":"10.33140/ahor.06.01.02","DOIUrl":"https://doi.org/10.33140/ahor.06.01.02","url":null,"abstract":"Background: Kaposi’s sarcoma is a mesenchymal proliferative process of blood and lymphatic system cells. The must well-known risk factors are immunosuppression and human herpes virus. Non-HIV related Kaposi’s sarcoma is a rare indolent entity that is more common among people of Mediterranean origin. Patients and Methods: The purpose of this retrospective analysis was to review a series of 21 patients with nonAIDS associated Kaposi’s sarcoma who presented to the Department of Oncology at the University Hospital Tangier between 2017 and 2022. Data were extracted from medical records using a pre-established survey sheet. The objective of this work is to define the major clinical features, treatment outcomes, and risk factors of the classic Mediterranean form of the disease in North Africa. Results: Twenty-one patients with non-AIDS associated Kaposi’s sarcoma were identified, with ages ranging from 52 to 98 years; the male-to-female ratio was 17:3. All of our patients had the classic form of the disease with negative HIV serology. In 71% of cases, Kaposi’s sarcoma was limited to the skin, without lymph node or visceral involvement. The lesions were multiple in all cases, mostly bilateral, and most commonly localized to the skin of the lower extremities. A complete response was achieved in 50% of patients using systemic therapy, and no patients died from Kaposi’s sarcoma. Conclusion: Unlike Kaposi’s sarcoma in AIDS patients, non-AIDS associated Kaposi’s sarcoma from Mediterranean countries is less agressive and more responsive to systemic therapeutic strategies.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122862836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Top Twelve Cancers in Jamaica 2008 2008年牙买加12大癌症
Pub Date : 2023-01-27 DOI: 10.33140/ahor.06.01.01
Researc H Article, Laten Andre, Mclish
Objective: To determine the top twelve cancers in Jamaica in the year 2008 and to examine the distribution of cancer of the endometrium as well as non-Hodgkin’s lymphoma in 2008. Methods: The study included all fourteen parishes. Data was obtained from the Jamaica Cancer Registry located in the Pathology Department of the University of the West Indies. Population denominators were obtained from the 2011 census taken by the Statistical Institute of Jamaica. The statistical package which was used to analyze the data was SPSS. Results: The top twelve cancers were determined using the crude incidence rate (CIR). In descending order, the top twelve cancers were prostate cancer (36.6), cancer of the breast (25.7), cancer of the cervix (23.2), cancer of the lung (7.0), cancer of the endometrium (6.9), cancer of the colon (5.2), carcinoma primary unknown (4.4), non-Hodgkin’s lymphoma (3.5), cancer of the stomach (3.0), cancer of the skin (2.6), cancer of the urinary bladder (1.8), cancer of the rectum (1.8) and cancer of the thyroid (1.1). It was also determined that cancer of the endometrium is mostly prevalent in the age group 55 years to 79 years and the highest probability of developing this cancer would be in the parishes of Kingston and St. Andrew and St. Catherine. In the case of non-Hodgkin’s lymphoma, it is mostly prevalent in the age group 45 years to 64 years. In Jamaica in 2008 it was more dominant in females than males (male/female ratio, 0.83). Based on the crude incidence rate, the highest probability of developing this cancer occurred in the parishes of Kingston and St. Andrew and St. Catherine. Conclusion: In mitigating against cancer, it is important to study the onset, the age groups affected as well as gender. It is also important to look at geographical locations to see the probability of developing a particular type of cancer. Once this is done then appropriate screening and safety protocols should be followed by the various health administrators.
目的:确定2008年牙买加最常见的12种癌症,并研究2008年子宫内膜癌和非霍奇金淋巴瘤的分布。方法:对全国14个教区进行调查。数据来自西印度群岛大学病理科的牙买加癌症登记处。人口分母来自牙买加统计研究所2011年的人口普查。采用SPSS统计软件对数据进行分析。结果:采用粗发病率(CIR)确定前12位肿瘤。按降序排列,排在前12位的癌症依次是前列腺癌(36.6)、乳腺癌(25.7)、宫颈癌(23.2)、肺癌(7.0)、子宫内膜癌(6.9)、结肠癌(5.2)、原发未知癌(4.4)、非霍奇金淋巴瘤(3.5)、胃癌(3.0)、皮肤癌(2.6)、膀胱癌(1.8)、直肠癌(1.8)和甲状腺癌(1.1)。研究还确定子宫内膜癌在55岁到79岁的人群中最为普遍患这种癌症的概率最高的地区是金斯顿,圣安德鲁和圣凯瑟琳的教区。在非霍奇金淋巴瘤的情况下,它主要流行于45岁至64岁年龄组。2008年在牙买加,女性比男性更占优势(男女比例为0.83)。根据粗发病率,患这种癌症的最高概率发生在金斯顿、圣安德鲁和圣凯瑟琳的教区。结论:研究肿瘤的发病、年龄、性别等因素对防治癌症具有重要意义。同样重要的是,要观察地理位置,以了解患某种特定癌症的可能性。一旦这样做,各卫生管理人员应遵循适当的筛查和安全方案。
{"title":"Top Twelve Cancers in Jamaica 2008","authors":"Researc H Article, Laten Andre, Mclish","doi":"10.33140/ahor.06.01.01","DOIUrl":"https://doi.org/10.33140/ahor.06.01.01","url":null,"abstract":"Objective: To determine the top twelve cancers in Jamaica in the year 2008 and to examine the distribution of cancer of the endometrium as well as non-Hodgkin’s lymphoma in 2008. Methods: The study included all fourteen parishes. Data was obtained from the Jamaica Cancer Registry located in the Pathology Department of the University of the West Indies. Population denominators were obtained from the 2011 census taken by the Statistical Institute of Jamaica. The statistical package which was used to analyze the data was SPSS. Results: The top twelve cancers were determined using the crude incidence rate (CIR). In descending order, the top twelve cancers were prostate cancer (36.6), cancer of the breast (25.7), cancer of the cervix (23.2), cancer of the lung (7.0), cancer of the endometrium (6.9), cancer of the colon (5.2), carcinoma primary unknown (4.4), non-Hodgkin’s lymphoma (3.5), cancer of the stomach (3.0), cancer of the skin (2.6), cancer of the urinary bladder (1.8), cancer of the rectum (1.8) and cancer of the thyroid (1.1). It was also determined that cancer of the endometrium is mostly prevalent in the age group 55 years to 79 years and the highest probability of developing this cancer would be in the parishes of Kingston and St. Andrew and St. Catherine. In the case of non-Hodgkin’s lymphoma, it is mostly prevalent in the age group 45 years to 64 years. In Jamaica in 2008 it was more dominant in females than males (male/female ratio, 0.83). Based on the crude incidence rate, the highest probability of developing this cancer occurred in the parishes of Kingston and St. Andrew and St. Catherine. Conclusion: In mitigating against cancer, it is important to study the onset, the age groups affected as well as gender. It is also important to look at geographical locations to see the probability of developing a particular type of cancer. Once this is done then appropriate screening and safety protocols should be followed by the various health administrators.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122467964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Modalities for Coronavirus SARS-CoV-2 (COVID-19) 冠状病毒SARS-CoV-2的治疗方法
Pub Date : 2022-08-22 DOI: 10.33140/ahor.05.01.06
The ongoing outbreak of coronavirus disease 2019 (COVID-19) that has accelerated in such short a period has spurred the investigation on existing and new therapeutic modalities. Therapeutic value of different classes of drugs have been tested including anti-parasites (Ivermectin), steroids (Dexamethasone), immune regulators (Tocilizumab), combination therapy MATH+ (Methylprednisolone, Ascorbic Acid, Thiamine), corticosteroid (Heparin), and antiviral medications (Molnupiravir or Paxlovid). Similarly, different types of vaccines, including mRNA-based vaccines, viral vector vaccines, and inactivated vaccines (requiring adjuvants) have also developed. Outbreaks of numerous COVID-19 variants, such as Omicron with rapid and frequent genomic mutations, have rendered vaccines less effectiveness against COVID-19. Due to short-term immune protection and treatment-induced adverse effects (e.g., vision problems, vertigo, diarrhea, nausea, allergic reaction, hypokalemia, hypertension, thrombosis with thrombocytopenia syndrome, Guillain-Bare syndrome, Bell’s palsy) boosters or secondary treatment is needed. Although various vaccines and therapeutics have been developed, further testing is required to obtain higher efficacy across age, gender, and race ranges and to establish long-term immunity. This review summarizes current treatment options available against COVID-19, their mechanisms of action, undesired side effects, as well as safety and efficacy protocols.
2019冠状病毒病(COVID-19)的持续爆发在如此短的时间内加速,促使人们对现有和新的治疗方式进行调查。已经测试了不同类别药物的治疗价值,包括抗寄生虫(伊维菌素)、类固醇(地塞米松)、免疫调节剂(托珠单抗)、联合治疗MATH+(甲基强的松龙、抗坏血酸、硫胺素)、皮质类固醇(肝素)和抗病毒药物(莫努比拉韦或Paxlovid)。同样,不同类型的疫苗,包括基于mrna的疫苗、病毒载体疫苗和灭活疫苗(需要佐剂)也已开发出来。许多COVID-19变体的爆发,如具有快速和频繁的基因组突变的欧米克隆,使疫苗对COVID-19的有效性降低。由于短期免疫保护和治疗引起的不良反应(如视力问题、眩晕、腹泻、恶心、过敏反应、低钾血症、高血压、血栓形成伴血小板减少综合征、格林- bare综合征、贝尔氏麻痹),需要增强剂或二次治疗。虽然已经开发了各种疫苗和治疗方法,但需要进一步的测试,以在不同年龄、性别和种族范围内获得更高的疗效,并建立长期免疫力。本综述总结了目前针对COVID-19的治疗方案、其作用机制、不良副作用以及安全性和有效性方案。
{"title":"Therapeutic Modalities for Coronavirus SARS-CoV-2 (COVID-19)","authors":"","doi":"10.33140/ahor.05.01.06","DOIUrl":"https://doi.org/10.33140/ahor.05.01.06","url":null,"abstract":"The ongoing outbreak of coronavirus disease 2019 (COVID-19) that has accelerated in such short a period has spurred the investigation on existing and new therapeutic modalities. Therapeutic value of different classes of drugs have been tested including anti-parasites (Ivermectin), steroids (Dexamethasone), immune regulators (Tocilizumab), combination therapy MATH+ (Methylprednisolone, Ascorbic Acid, Thiamine), corticosteroid (Heparin), and antiviral medications (Molnupiravir or Paxlovid). Similarly, different types of vaccines, including mRNA-based vaccines, viral vector vaccines, and inactivated vaccines (requiring adjuvants) have also developed. Outbreaks of numerous COVID-19 variants, such as Omicron with rapid and frequent genomic mutations, have rendered vaccines less effectiveness against COVID-19. Due to short-term immune protection and treatment-induced adverse effects (e.g., vision problems, vertigo, diarrhea, nausea, allergic reaction, hypokalemia, hypertension, thrombosis with thrombocytopenia syndrome, Guillain-Bare syndrome, Bell’s palsy) boosters or secondary treatment is needed. Although various vaccines and therapeutics have been developed, further testing is required to obtain higher efficacy across age, gender, and race ranges and to establish long-term immunity. This review summarizes current treatment options available against COVID-19, their mechanisms of action, undesired side effects, as well as safety and efficacy protocols.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121423783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serological Detection of Some Rhesus D Polymorphisms among Rhesus Negative Sudanese Blood Donors 苏丹恒河阴性献血者部分恒河猴D基因多态性的血清学检测
Pub Date : 2022-08-22 DOI: 10.33140/ahor.05.01.05
Background: Rhesus (Rh) blood group, mainly the D phenotype is subject to polymorphisms associated with several Rh D variants. The identification of such variants may prevent blood reactions due to Rh incompatibilities. Material and Methods: This descriptive cross-sectional study was conducted in Khartoum North, Khartoum-Sudan during the period from December 2021 to March 2022. A total of 100 blood donors who had Rh D negative grouping results were recruited for this study. All samples were tested for weak D and Rh-Del phenotypes by indirect antihuman globulin and adsorption-elution methods respectively. In addition, Rh CE typing was performed for all samples, then the association between Rh CE phenotype and Rh D variants was tested by Chi square test. P values of < 0.05 were considered statistically significant. Results: Among the tested donors, 7% were Rh-Del, 5% were weak D while the remaining 88% were truly Rh-negative phenotype. All Rh-Del subjects were Rh CE positive; 80% of weak D were Rh CE positive, while only 11% of truly Rh-negative donors were Rh CE positive. Statistically significant association was observed between Rh CE positive phenotype with Rh Del and weak D phenotypes, while truly negative Rh D phenotype is associated with negative Rh CE phenotypes (All P values < 0.05). Discussion: Variant D phenotypes were observed in this study population. Therefore, attention for this category among Rh D negative donors is needed to avoid allo immunization in truly negative patients.
背景:恒河猴(Rh)血型,主要是D型,受几种Rh D变异相关的多态性影响。这种变异的识别可以防止由于Rh不相容引起的血液反应。材料和方法:本描述性横断面研究于2021年12月至2022年3月期间在苏丹喀土穆北部喀土穆进行。这项研究共招募了100名Rh D阴性分组结果的献血者。所有样品分别采用间接抗人球蛋白法和吸附-洗脱法检测弱D和Rh-Del表型。此外,对所有样本进行Rh CE分型,然后通过卡方检验检验Rh CE表型与Rh D变异之间的相关性。P值< 0.05认为有统计学意义。结果:在检测的供体中,7%为Rh-Del, 5%为弱D,其余88%为真正的rh阴性表型。所有Rh- del受试者Rh CE阳性;80%的弱D是Rh CE阳性,而真正Rh阴性的献血者中只有11%是Rh CE阳性。Rh CE阳性表型与Rh Del、弱D表型有统计学意义相关,Rh D真阴性表型与Rh CE阴性表型相关(P值均< 0.05)。讨论:在本研究人群中观察到变异的D表型。因此,需要在Rh D阴性献血者中注意这一类别,以避免在真正阴性患者中进行allow免疫。
{"title":"Serological Detection of Some Rhesus D Polymorphisms among Rhesus Negative Sudanese Blood Donors","authors":"","doi":"10.33140/ahor.05.01.05","DOIUrl":"https://doi.org/10.33140/ahor.05.01.05","url":null,"abstract":"Background: Rhesus (Rh) blood group, mainly the D phenotype is subject to polymorphisms associated with several Rh D variants. The identification of such variants may prevent blood reactions due to Rh incompatibilities. Material and Methods: This descriptive cross-sectional study was conducted in Khartoum North, Khartoum-Sudan during the period from December 2021 to March 2022. A total of 100 blood donors who had Rh D negative grouping results were recruited for this study. All samples were tested for weak D and Rh-Del phenotypes by indirect antihuman globulin and adsorption-elution methods respectively. In addition, Rh CE typing was performed for all samples, then the association between Rh CE phenotype and Rh D variants was tested by Chi square test. P values of < 0.05 were considered statistically significant. Results: Among the tested donors, 7% were Rh-Del, 5% were weak D while the remaining 88% were truly Rh-negative phenotype. All Rh-Del subjects were Rh CE positive; 80% of weak D were Rh CE positive, while only 11% of truly Rh-negative donors were Rh CE positive. Statistically significant association was observed between Rh CE positive phenotype with Rh Del and weak D phenotypes, while truly negative Rh D phenotype is associated with negative Rh CE phenotypes (All P values < 0.05). Discussion: Variant D phenotypes were observed in this study population. Therefore, attention for this category among Rh D negative donors is needed to avoid allo immunization in truly negative patients.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134146391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potentiation of Efficacy of Chimeric Antigen Receptor (CAR) T-cell Therapy in Hematological Malignancies using FDA-Approved Small Molecule Sensitizing Agents 使用fda批准的小分子增敏剂增强嵌合抗原受体(CAR) t细胞治疗血液系统恶性肿瘤的疗效
Pub Date : 2022-01-30 DOI: 10.33140/ahor.05.01.03
Chimeric antigen receptor CD19 CAR T-cell therapy has received FDA-approval for treatment of B cell malignancies. CD19 is an ideal target for B cell malignancies due to its limited expression by B lineage cells. Non-Hodgkin’s Lymphoma of B-cell origin (NHL B-cell) accounts for about 4% of all cancers in the United States. Traditionally, combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was considered as standard treatment option for NHL patients. However, a subset of individuals was inherently resistant to CHOP or developed resistance upon continued exposure to chemotherapy. The development of drug-resistance, plus the undesired toxic side effects of this regimen, led to the inclusion of anti-CD20 mAb, Rituximab, to chemotherapy protocols of NHL patients (R-CHOP). Superior improvement was observed in patients undergoing R-CHOP compared to CHOP. More recently, chimeric antigen receptor (CAR) T-Cells redirected against CD19 (CD19 CAR T-cell) has proven to be an effective immunotherapy against various cancers including NHL. Despite initial success, and like other approaches, NHL patients become unresponsive to CD19 CAR T-Cells due to selective outgrowth of NHLs with deregulated expression of apoptotic proteins. Histone deacetylase inhibitors (HDACis) and celecoxib have gene regulatory effects and skew the tumor intracellular environment into a proapoptotic milieu. Thus, resistant NHL cells will become sensitized to apoptotic death signals delivered by CD19 CAR T-Cells. We propose the inclusion of FDA-approved small molecules as sensitizing agents to reduce the apoptosis threshold of resistant NHL and boost CD19 CAR T-cell efficacy
嵌合抗原受体CD19 CAR - t细胞疗法已获得fda批准用于治疗B细胞恶性肿瘤。由于CD19在B系细胞中的表达有限,它是B细胞恶性肿瘤的理想靶点。b细胞源性非霍奇金淋巴瘤(NHL b细胞)约占美国所有癌症的4%。传统上,环磷酰胺、阿霉素、长春新碱、强的松联合化疗(CHOP)被认为是NHL患者的标准治疗选择。然而,一小部分个体天生对CHOP有耐药性,或在持续接受化疗后产生耐药性。耐药的发展,加上该方案不希望出现的毒副作用,导致抗cd20单抗利妥昔单抗被纳入NHL患者的化疗方案(R-CHOP)。与CHOP相比,R-CHOP患者的改善更明显。最近,靶向CD19的嵌合抗原受体(CAR) t细胞(CD19 CAR - t细胞)已被证明是一种有效的免疫疗法,可治疗包括NHL在内的各种癌症。尽管最初取得了成功,但与其他方法一样,NHL患者对CD19 CAR - t细胞没有反应,这是由于NHL选择性生长导致凋亡蛋白表达失调。组蛋白去乙酰化酶抑制剂(HDACis)和塞来昔布具有基因调控作用,使肿瘤细胞内环境进入促凋亡环境。因此,耐药NHL细胞会对CD19 CAR - t细胞传递的凋亡死亡信号变得敏感。我们建议纳入fda批准的小分子增敏剂,以降低耐药NHL的凋亡阈值并提高CD19 CAR - t细胞的疗效
{"title":"Potentiation of Efficacy of Chimeric Antigen Receptor (CAR) T-cell Therapy in Hematological Malignancies using FDA-Approved Small Molecule Sensitizing Agents","authors":"","doi":"10.33140/ahor.05.01.03","DOIUrl":"https://doi.org/10.33140/ahor.05.01.03","url":null,"abstract":"Chimeric antigen receptor CD19 CAR T-cell therapy has received FDA-approval for treatment of B cell malignancies. CD19 is an ideal target for B cell malignancies due to its limited expression by B lineage cells. Non-Hodgkin’s Lymphoma of B-cell origin (NHL B-cell) accounts for about 4% of all cancers in the United States. Traditionally, combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was considered as standard treatment option for NHL patients. However, a subset of individuals was inherently resistant to CHOP or developed resistance upon continued exposure to chemotherapy. The development of drug-resistance, plus the undesired toxic side effects of this regimen, led to the inclusion of anti-CD20 mAb, Rituximab, to chemotherapy protocols of NHL patients (R-CHOP). Superior improvement was observed in patients undergoing R-CHOP compared to CHOP. More recently, chimeric antigen receptor (CAR) T-Cells redirected against CD19 (CD19 CAR T-cell) has proven to be an effective immunotherapy against various cancers including NHL. Despite initial success, and like other approaches, NHL patients become unresponsive to CD19 CAR T-Cells due to selective outgrowth of NHLs with deregulated expression of apoptotic proteins. Histone deacetylase inhibitors (HDACis) and celecoxib have gene regulatory effects and skew the tumor intracellular environment into a proapoptotic milieu. Thus, resistant NHL cells will become sensitized to apoptotic death signals delivered by CD19 CAR T-Cells. We propose the inclusion of FDA-approved small molecules as sensitizing agents to reduce the apoptosis threshold of resistant NHL and boost CD19 CAR T-cell efficacy","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121124066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenchymal Stem Cells Can Alleviate Tuberculosis Infection and Transmission 间充质干细胞可减轻结核感染和传播
Pub Date : 2022-01-09 DOI: 10.33140/ahor.05.01.01
Mesenchymal stem cells are increasingly becoming a topic of interest for their breadth of treatment for a range of complications in the medical field. Their unique abilities to restore damaged tissue and modulate various aspects of the immune system are understood, and more studies continue to reveal other therapeutic aspects. Some studies have begun to focus on their potential as a treatment for Tuberculosis, a complex disease caused by a population of bacteria in host tissue environments. There is currently no cure for this disease, which has developed resistance to a range of drugs over the course of history, and a novel therapeutic is required in order to effectively treat and eventually eradicate the disease. In this paper, we discuss the potential immunomodulatory and tissue-repairing effects of mesenchymal stem cells that hint to their efficacy as a treatment for the disease. We also consider the reality of distributing this advanced therapeutic to regions of the world where Tuberculosis is most prevalent. Based on these countries’ political and economic infrastructures and the emergence of other disease, mesenchymal stem cells may not be a treatment that can realized soon to treat those most affected by Tuberculosis.
间充质干细胞因其治疗一系列并发症的广度而日益成为医学界关注的话题。它们恢复受损组织和调节免疫系统各方面的独特能力已被了解,更多的研究继续揭示其他治疗方面。一些研究已经开始关注它们治疗结核病的潜力,结核病是一种由宿主组织环境中的细菌群引起的复杂疾病。目前还没有治愈这种疾病的方法,在历史进程中,这种疾病已经对一系列药物产生了耐药性,为了有效治疗并最终根除这种疾病,需要一种新的治疗方法。在本文中,我们讨论了间充质干细胞潜在的免疫调节和组织修复作用,暗示其治疗疾病的功效。我们还考虑到将这种先进的治疗方法分发到世界上结核病最流行的地区的现实。根据这些国家的政治和经济基础设施以及其他疾病的出现,间充质干细胞可能不会很快成为一种治疗受结核病影响最严重的人的方法。
{"title":"Mesenchymal Stem Cells Can Alleviate Tuberculosis Infection and Transmission","authors":"","doi":"10.33140/ahor.05.01.01","DOIUrl":"https://doi.org/10.33140/ahor.05.01.01","url":null,"abstract":"Mesenchymal stem cells are increasingly becoming a topic of interest for their breadth of treatment for a range of complications in the medical field. Their unique abilities to restore damaged tissue and modulate various aspects of the immune system are understood, and more studies continue to reveal other therapeutic aspects. Some studies have begun to focus on their potential as a treatment for Tuberculosis, a complex disease caused by a population of bacteria in host tissue environments. There is currently no cure for this disease, which has developed resistance to a range of drugs over the course of history, and a novel therapeutic is required in order to effectively treat and eventually eradicate the disease. In this paper, we discuss the potential immunomodulatory and tissue-repairing effects of mesenchymal stem cells that hint to their efficacy as a treatment for the disease. We also consider the reality of distributing this advanced therapeutic to regions of the world where Tuberculosis is most prevalent. Based on these countries’ political and economic infrastructures and the emergence of other disease, mesenchymal stem cells may not be a treatment that can realized soon to treat those most affected by Tuberculosis.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114919533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclical Preponderance of Gastrointestinal Parasites and their impact on Small ruminants around Gwalior (Madhya Pradesh) India 印度瓜廖尔(中央邦)地区胃肠道寄生虫的周期性优势及其对小型反刍动物的影响
Pub Date : 2022-01-09 DOI: 10.33140/ahor.05.01.02
In India, the Livestock sector plays an important role in the economy and is one of the most potential sub-sectors of agriculture which plays a necessary role in promoting human health and most particularly in central India, Small ruminants like (sheep and goat) constitute the major portion of livestock. Gwalior is considered as a Semi-Central Zone where different tribes particularly Gujjar’s and Bakerwals had made cattle rearing as their professional business. The production and productivity of small ruminants in Gwalior state are greatly hindered by various diseases including gastro-intestinal parasitic infection which is caused due to improper care, unhygienic environmental conditions, harsh and hot climatic setup, and close contact with other infected animals. Gastrointestinal parasitism is a global problem. Therefore, a one-year-long epizootic survey was conducted to study the prevalence of gastrointestinal parasites and their various species present in small ruminants (goats/sheep) in the Gwalior region. From January 2019 to January 2020, a total of 338 faecal samples from goats of different locations in Gwalior (MP) India were examined to confirm the presence of parasites and gastrointestinal parasitic infections. Majority of the samples were found positive for endoparasites and goats were also detected positive for gastrointestinal parasites. In Goat, the overall incidence of Haemonchus, Coccidia, Trichuris, Nematodirus, and Fasciola were 47.6%, 36.5%, 39.6% respectively. The occurrence of Nematodirus and Fasciola (20.9%, 2.32%) has been observed in sheep only.
在印度,畜牧业在经济中发挥着重要作用,是农业中最具潜力的分部门之一,在促进人类健康方面发挥着必要的作用,特别是在印度中部,(绵羊和山羊)等小型反刍动物构成了牲畜的主要部分。瓜廖尔被认为是一个半中心区,不同的部落,特别是古贾尔人和贝克瓦尔人,把养牛作为他们的专业业务。瓜廖尔州小反刍动物的生产和生产力受到各种疾病的极大阻碍,包括胃肠道寄生虫感染,这种疾病是由于照顾不当、不卫生的环境条件、恶劣和炎热的气候条件以及与其他受感染动物的密切接触而引起的。胃肠道寄生虫病是一个全球性问题。为此,对瓜廖尔地区小反刍动物(山羊/绵羊)胃肠道寄生虫的流行情况及其种类进行了为期一年的动物调查。2019年1月至2020年1月,对印度瓜廖尔不同地点的山羊共338份粪便样本进行了检查,以确认寄生虫和胃肠道寄生虫感染的存在。大多数山羊体内寄生虫呈阳性,胃肠道寄生虫也呈阳性。山羊血螨、球虫、滴虫、线虫和片形吸虫的总感染率分别为47.6%、36.5%和39.6%。线虫病和片形虫的感染率分别为20.9%和2.32%。
{"title":"Cyclical Preponderance of Gastrointestinal Parasites and their impact on Small ruminants around Gwalior (Madhya Pradesh) India","authors":"","doi":"10.33140/ahor.05.01.02","DOIUrl":"https://doi.org/10.33140/ahor.05.01.02","url":null,"abstract":"In India, the Livestock sector plays an important role in the economy and is one of the most potential sub-sectors of agriculture which plays a necessary role in promoting human health and most particularly in central India, Small ruminants like (sheep and goat) constitute the major portion of livestock. Gwalior is considered as a Semi-Central Zone where different tribes particularly Gujjar’s and Bakerwals had made cattle rearing as their professional business. The production and productivity of small ruminants in Gwalior state are greatly hindered by various diseases including gastro-intestinal parasitic infection which is caused due to improper care, unhygienic environmental conditions, harsh and hot climatic setup, and close contact with other infected animals. Gastrointestinal parasitism is a global problem. Therefore, a one-year-long epizootic survey was conducted to study the prevalence of gastrointestinal parasites and their various species present in small ruminants (goats/sheep) in the Gwalior region. From January 2019 to January 2020, a total of 338 faecal samples from goats of different locations in Gwalior (MP) India were examined to confirm the presence of parasites and gastrointestinal parasitic infections. Majority of the samples were found positive for endoparasites and goats were also detected positive for gastrointestinal parasites. In Goat, the overall incidence of Haemonchus, Coccidia, Trichuris, Nematodirus, and Fasciola were 47.6%, 36.5%, 39.6% respectively. The occurrence of Nematodirus and Fasciola (20.9%, 2.32%) has been observed in sheep only.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"146 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122780479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Hematology and Oncology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1